[go: up one dir, main page]

ES2178961B1 - Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas. - Google Patents

Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas.

Info

Publication number
ES2178961B1
ES2178961B1 ES200100530A ES200100530A ES2178961B1 ES 2178961 B1 ES2178961 B1 ES 2178961B1 ES 200100530 A ES200100530 A ES 200100530A ES 200100530 A ES200100530 A ES 200100530A ES 2178961 B1 ES2178961 B1 ES 2178961B1
Authority
ES
Spain
Prior art keywords
maleic anhydride
nanoparticles
drug
administration
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200100530A
Other languages
English (en)
Other versions
ES2178961A1 (es
Inventor
Pau Arbos Vila
Marta Merodio de la Quintana
Amaia Arnedo Hernandez
Felix Recarte Flamarique
Maria J. Renedo Omaecheverria
Juan M. Irache Garreta
Maria Socorro Espuelas Millan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto Cientifico y Tecnologico de Navarra SA
Original Assignee
Instituto Cientifico y Tecnologico de Navarra SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Cientifico y Tecnologico de Navarra SA filed Critical Instituto Cientifico y Tecnologico de Navarra SA
Priority to ES200100530A priority Critical patent/ES2178961B1/es
Priority to PCT/ES2002/000098 priority patent/WO2002069938A1/es
Priority to US10/467,983 priority patent/US20050079222A1/en
Priority to EP02708372A priority patent/EP1369110A1/en
Publication of ES2178961A1 publication Critical patent/ES2178961A1/es
Application granted granted Critical
Publication of ES2178961B1 publication Critical patent/ES2178961B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Dispersion Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Fabricación de nanopartículas a base del copolímero de metil y vinil éter y anhídrido maleico para la administración de fármacos de naturaleza hidrofílica, en particular de bases púricas y pirimidínicas. Las nanopartículas se obtienen por desolvatación con una fase hidroalcohólica de una solución en acetona del copolímero de metil vinil éter y anhídrido maleico. Posteriormente, las partículas obtenidas se tratan con agentes reticulantes (diaminas o proteínas) con el fin de alargar su vida útil y, eventualmente, se incuban con un fármaco que será transportado en superficie. Las nanopartículas pueden llevar el fármaco también encapsulado que se añadiría entonces durante la desolvatación. En el caso de los conjugados nanopartículaligando, las nanopartículas previamente obtenidas y conteniendo en su interior el fármaco a transportar se incuban con el ligando o molécula que aportará la propiedad de reconocer de manera específica un determinado receptor del organismo. Estas formas farmacéuticas tienen como objetivo mejorar el transporte del fármaco o molécula biológicamente activa a su lugar de acción y/o absorción. Esta propiedad mejora la especificidad y eficacia de dichos fármacos.
ES200100530A 2001-03-06 2001-03-06 Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas. Expired - Fee Related ES2178961B1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES200100530A ES2178961B1 (es) 2001-03-06 2001-03-06 Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas.
PCT/ES2002/000098 WO2002069938A1 (es) 2001-03-06 2002-03-06 Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas
US10/467,983 US20050079222A1 (en) 2001-03-06 2002-03-06 Production of nanoparticles from methyl vinyl ether and maleic anhydride for the administration of hydrophilic pharmaceuticals, more particularly of puric and pyrimidinic bases
EP02708372A EP1369110A1 (en) 2001-03-06 2002-03-06 Production of nanoparticles from methyl vinyl ether copolymer and maleic anhydride for the administration of hydrophilic pharmaceuticals, more particularly of puric and pyrimidinic bases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100530A ES2178961B1 (es) 2001-03-06 2001-03-06 Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas.

Publications (2)

Publication Number Publication Date
ES2178961A1 ES2178961A1 (es) 2003-01-01
ES2178961B1 true ES2178961B1 (es) 2004-07-01

Family

ID=8496996

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200100530A Expired - Fee Related ES2178961B1 (es) 2001-03-06 2001-03-06 Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas.

Country Status (4)

Country Link
US (1) US20050079222A1 (es)
EP (1) EP1369110A1 (es)
ES (1) ES2178961B1 (es)
WO (1) WO2002069938A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012156564A2 (es) 2011-05-19 2012-11-22 Universidade De Santiago De Compostela Microesferas poliméricas como adyuvantes en la producción de vacunas frente a parásitos escuticociliados de peces

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246695B1 (es) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
ES2286951B1 (es) * 2006-05-26 2008-10-01 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas bioadhesivas para la administracion de moleculas biologicamente activas.
ES2310122B1 (es) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
ES2327375B1 (es) 2007-11-14 2010-08-05 Universidad Del Pais Vasco Empleo de microparticulas para su uso como vacunas y la liberacion de moleculas biologicamente activas.
ES2328001B1 (es) * 2007-12-07 2010-09-20 Consejo Superior De Investigaciones Cientificas (60%) Composicion de gentamicina, un surfactante anionico, y un copolimero.
WO2011139218A1 (en) * 2010-05-04 2011-11-10 General Electric Company Nucleic acid delivery vehicle uses thereof
EP2510930A1 (en) 2011-04-15 2012-10-17 Bionanoplus, S.L. Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
US20130004651A1 (en) * 2011-07-01 2013-01-03 Patty Fu-Giles Sustained drug release from body implants using nanoparticle-embedded polymeric coating materials
CA2997423A1 (en) 2015-09-14 2017-03-23 Saudi Arabian Oil Company Maleic anhydride polymers and methods of treating subterranean formations
US10005930B2 (en) 2015-09-14 2018-06-26 Saudi Arabian Oil Company Pendant epoxide polymers and methods of treating subterranean formations
RU2628881C2 (ru) * 2015-12-17 2017-08-22 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" Гидролизуемая кислотой композиция, включающая частицы микрогеля, для доставки лекарств в живые организмы и способ ее получения
CN109906262A (zh) 2016-11-04 2019-06-18 沙特阿拉伯石油公司 用于封堵与凝固水泥接触的流动通道的组合物和方法
US10526458B1 (en) * 2018-12-18 2020-01-07 Saudi Arabian Oil Company Gellable, non-aqueous oil well treatment fluids comprising elastomeric maleic anhydride copolymers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
AU629316B2 (en) * 1990-04-11 1992-10-01 Flora Inc. Periodontal disease treatment system
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
FR2721510B1 (fr) * 1994-06-22 1996-07-26 Rhone Poulenc Rorer Sa Nanoparticules filtrables dans des conditions stériles.
FR2762394B1 (fr) * 1997-04-16 1999-05-28 Bio Merieux Compose ligand de coordination et utilisation pour fixer un materiel biologique
US6229009B1 (en) * 1997-08-29 2001-05-08 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Polycarboxylic based cross-linked copolymers
US7217735B1 (en) * 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARNEDO, A. et al. "Determination of oligonucleotide ISIS 2922 in nanoparticlate delivery systems by capillary zone electrophoresis", Journal of Chromatography, A. Netherlands, 25 Feb. 2000, Volumen 871, Nº 1-2, páginas 311-320, (resumen) Medline (en línea) Bethesda, MD (EE.UU): Unites States National Library of Medicina [recuperado el 03.06.2002]. Recuperado de: EPO MEDLINE/NLM. Nº de acceso de Medline 10735311. *
J.J. MARTY et al. "Nanoparticles - a New Colloidal Drug Delivery System" Pharm. Acta Helv. 53 (1), 17-23 (1978); Summary, página 21, párrafo 2º; página 22, punto 3.1, líneas 1-3. *
MERODIO, M. et al. "Development of a sensitive method for the determination of ganciclovir by reversed-phase high-performance liquid chromatography", Journal of Chromatography, A. Netherlands, 18 Feb. 2000, Volumen 870, Nº 1-2, páginas 159-167, (resumen) Medline (en línea) Bethesda, MD (EE.UU): United States National Library of Medicina [recuperado el 03.06.2002]. Recuperado de: EPO MEDLINE/NLM. Nº de acceso de Medline 10722073. *
YALABIK-HAS, H.S. et al. "Sorption of 5-fluorouracil from aqueous solutions onto methyl methacrylate nanoparticles", Journal of Microencapsulation, England, Abr-Jun 1986, Volumen 3, Nº 2, páginas 71-75, (resumen). Medline (en línea) Bethesda, MD (EE.UU): United States National Library of Medicina [recuperado el 03.06.2002]. Recuperado de: EPO MEDLINE/NLM. Nº de acceso de Medline 3508180. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012156564A2 (es) 2011-05-19 2012-11-22 Universidade De Santiago De Compostela Microesferas poliméricas como adyuvantes en la producción de vacunas frente a parásitos escuticociliados de peces

Also Published As

Publication number Publication date
EP1369110A1 (en) 2003-12-10
ES2178961A1 (es) 2003-01-01
WO2002069938A1 (es) 2002-09-12
US20050079222A1 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
ES2178961B1 (es) Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas.
Shinde et al. Methotrexate: a gold standard for treatment of rheumatoid arthritis
CY1123110T1 (el) Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου
BRPI0414000B8 (pt) composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
CY1107128T1 (el) Φαρμακευτικα σκευασματα αερολυματος
ES2249888T3 (es) Conjugados de paclitaxel solubles en agua, combinados con irradiacion para el tratamiento del cancer.
ATE356612T1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
DE60315145D1 (de) Hydrophiles polymerderivat mit y-verzweigung und herstellungsverfahren dafür; obige verbindung enthaltender medizinischer verbundwerkstoff
EA200301279A1 (ru) Фармацевтические композиции адсорбатов аморфного лекарственного средства
AR082579A2 (es) Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad
CL2008003595A1 (es) Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central.
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
ECSP003847A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
DE60330322D1 (de) Arzneimittel-mikroteilchen
AR072596A1 (es) Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico
PA8594801A1 (es) Formulaciones farmaceuticas liquidas de palanosetron
AR072668A1 (es) Encapsulacion de agentes biologicamente activos
ATE527254T1 (de) Mit imidazol enthaltenden sekundären aminen substituierte benzopyran-derivate, deren herstellung und diese enthaltende pharmazeutische zubereitungen
Xue et al. Porous silicon nanocarriers with stimulus‐cleavable linkers for effective cancer therapy
ATE367803T1 (de) Subcutane implantate mit begrenzter initialer wirkstoff-freisetzung und deren anschliessende lineare veränderliche verlängerte freisetzung
Ren et al. Nanomedicines targeting metabolism in the tumor microenvironment
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
WO2006007354A3 (en) A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device
AR048342A1 (es) FORMAS DE DOSIFICACIoN FARMACÉUTICAS QUE COMPRENDEN EL ÁCIDO N-(2-(2-FTALIMIDOETOXI)-ACETIL)-L-ALANIL-D-GLUTÁMICO (LK-423)
EP1562563A4 (en) METHOD FOR THE TREATMENT OF DISEASES WITH LACK OF THI-PURE CONNECTION

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030101

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2178961B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180807